Treatment of cancer by inhibiting activity or expression of late SV-40 factor

Patent metadata

Field	Value
Publication number	US-9283244-B2
Application number	US-201113636815-A
Country	US
Kind code	B2
Filing date	Mar 29, 2011
Priority date	Apr 1, 2010
Publication date	Mar 15, 2016
Grant date	Mar 15, 2016

Abstract

Inhibitors of Late SV-40 Factor (LSF) are used to treat cancers such as hepatocellular carcinoma (HCC). In particular, small molecule chemical LSF inhibitors are employed. In addition, the activity and/or pattern of expression of LSF may is used to diagnose cancer, to characterize the cancer (e.g. stage, grade, prognosis, etc.) and also to develop suitable protocols for cancer treatment.

First claim

We claim:

1. A method of inhibiting or reducing tumor growth associated with cancer in vivo in a subject, comprising the step of
limiting expression or activity of Late SV40 Factor (LSF) activity in vivo in said subject, wherein said LSF inhibitor compound targets at least one DNA binding domain of LSF.

2. The method of claim 1 , wherein said cancer is hepatocellular carcinoma (HCC).

3. The method of claim 1 , wherein said at least one DNA binding domain of LSF is an osteopontin (OPN) promoter binding domain.

4. A method of promoting damage or death of cancer cells in vivo in a subject, comprising the step of
limiting expression or activity of Late SV40 Factor (LSF) activity in vivo in said subject, and wherein said step of limiting includes a step of administering to said subject one or more of an LSF inhibitor compound, anti-LSF inhibitory RNA, and anti-LSF antibodies, and wherein said LSF inhibitor compound targets at least one DNA binding domain of LSF.

5. The method of claim 4 , wherein said cancer cells are from hepatocellular carcinoma.

6. The method of claim 4 , wherein said at least one DNA binding domain of LSF is an osteopontin (OPN) promoter binding domain.

Assignees

• Sarkar Devanand
• Fisher Paul B
• Univ Virginia Commonwealth

Inventors

• Sarkar Devanand
• Fisher Paul B

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C12Q2600/136

  Screening for pharmacological compounds · CPC title

• C07K16/303

  Liver or Pancreas · CPC title

• A61K31/7105 Primary

  Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title